Longitudinal Heart Failure Medication Use and Adherence Following Left Ventricular Assist Device Implantation in Privately Insured Patients

Nicholas Y. Tan, MD, MS; Lindsey R. Sangaralingham, MPH; Stephanie R. Schilz, BA; Shannon M. Dunlay, MD, MS

Background—There are few data describing the longitudinal use of and adherence to heart failure medications following left ventricular assist device (LVAD) implantation.

Methods and Results—Using a large US commercial insurance database, patients who received an LVAD (International Classification of Diseases, 9th Revision, Clinical Modification code 37.66) and survived to hospital discharge without heart transplantation between January 1, 2006, and March 31, 2015, were identified. Heart failure medication use from 3 months before 1-year post-LVAD was examined using linked pharmacy claims. Differences in the proportion of patients taking heart failure medications post LVAD compared with pre LVAD were examined using McNemar test. Predictors of post-LVAD medication use and poor medication adherence (proportion of days covered < 0.8) were identified via logistic regression. Among 362 patients (mean age, 57.4 years; 75.1% men), compared with pre LVAD, the proportion of patients taking anticoagulants and antiarrhythmics following LVAD increased; mineralocorticoid receptor antagonists, thiazide diuretics, and digoxin decreased; and β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and loop diuretics did not change. Pre-LVAD medication use was associated with post-LVAD use across all medication classes. The proportion of patients with poor medication adherence was 28.8%, 39.0%, and 36.0% for β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and anticoagulants, respectively. Many patients with poor adherence completely discontinued use of the medication.

Conclusions—Neurohormonal antagonist use after LVAD was inconsistent, perhaps reflecting uncertainty of therapeutic benefit in this population. Medication adherence post-LVAD was poor in many patients. Further work is needed to delineate the reasons for nonadherence after LVAD. (J Am Heart Assoc. 2017;6:e005776. DOI: 10.1161/JAHA.117.005776.)

Key Words: advanced heart failure • left ventricular assist device • medication adherence

The past decade has seen tremendous advances in left ventricular assist device (LVAD) technology. As a result, its use in the treatment of advanced heart failure (HF) has expanded over time. Yet, despite the growing use of LVADs, there are few data available to guide the use of HF medications following implantation. The 2013 International Society of Heart and Lung Transplant (ISHLT) mechanical circulatory support guidelines provide only brief recommendations for HF medical therapies in patients with LVAD that were based on insights gleaned from small retrospective studies and/or theoretical knowledge of their biological effects in HF. Furthermore, unlike management of HF with reduced ejection fraction, the use of some medication classes including β-blockers are not universally recommended after LVAD. Nearly all HF medications classes would benefit from further study to define their role in the medical management of patients with LVADs. However, without these further studies, clinicians who manage patients with LVADs are often reliant upon clinical judgment and extrapolation of evidence from other settings in choosing medical therapy. As such, evaluation of observational data can provide meaningful insight into current practice patterns.

A single recent study using Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) data...
Clinical Perspective

What Is New?

- We investigated heart failure medication use before and following left ventricular assist device (LVAD) implantation among 362 commercially insured patients.
- Use of mineralocorticoid receptor antagonists decreased post-LVAD implantation, whereas the use of β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and diuretics did not change.
- The only consistent predictor of post-LVAD medication use was use of a medication in the same therapeutic class pre LVAD.
- One fifth of patients were not on anticoagulation after LVAD.
- Many patients had poor adherence to β-blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers post LVAD, some of whom completely discontinued use of these medications.

What Are the Clinical Implications?

- Evidence to guide the use of neurohormonal antagonists after LVAD is lacking, resulting in variability in treatment across clinical practice.
- Patients are often maintained on the same medications post LVAD that they were taking pre LVAD, and many are not initiated on β-blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, although these agents may be better tolerated as a result of improved hemodynamics post LVAD.
- Further studies are needed to elucidate the reasons for medication nonadherence following LVAD implantation.

Methods

We conducted a retrospective analysis of administrative claims data from a large US commercial insurance database, Optum Labs Data Warehouse, which is comprised of privately insured enrollees from geographically diverse regions across the country. The database includes professional, facility, and outpatient medication service claims for individuals enrolled in private and Medicare Advantage health plans. Because this study involved analysis of preexisting, de-identified data, it was exempt from institutional review board approval.

Study Population

We identified all patients 18 years and older who underwent LVAD implantation (International Classification of Diseases, 9th Revision [ICD-9] procedure code 37.66) and survived to hospital discharge without undergoing heart transplantation (ICD-9 procedure code 37.51) between January 1, 2006, and March 31, 2015. To capture baseline patient medication use and comorbidities, we restricted the analysis to patients who had medical and pharmacy coverage for at least 6 months before LVAD implantation. Furthermore, as our goal was to capture post-LVAD medication use, we also excluded patients with medical and pharmacy coverage for <3 months post-LVAD implantation. Because medication management changes after heart transplantation, we also excluded patients who underwent heart transplantation within 3 months post LVAD.

Patient Characteristics

For each patient, we assessed demographic and clinical characteristics during their baseline period, including age, sex, race, and selected comorbidities. Baseline medical comorbidities (including hypertension, diabetes mellitus, cerebrovascular disease, renal disease, and cardiac arrhythmias) were captured by ICD-9 codes in one of the first 3 positions on claims taking place within 180 days before LVAD implantation (Table S1).

Hospital Characteristics

The American Hospital Association (AHA) data were used to elucidate the characteristics of the hospitals where enrollees had LVADs implanted; 22.7% of patients were missing these data. AHA variables examined included hospital location (rural, micro, metro, or division); bed size; geographic region (Northeast, Midwest, South, and West), and teaching status (ie, those belonging to the Council of Teaching Hospitals of the Association of American Medical Colleges).

Medication Use and Adherence

We examined pharmacy claims from 3 months before 12 months post-LVAD implantation to determine patient
medication use through June 30, 2015. Patients were censored from analysis at the time of heart transplantation (ICD-9 code 37.51) or at the end of medical/pharmacy coverage. In addition to examining the evidence-based medications shown to improve outcomes in HF with reduced ejection fraction (β-blockers, ACEIs and ARBs, MRAs), we also examined use of commonly prescribed medication classes after LVAD, including loop diuretics; anticoagulants (warfarin, low-molecular-weight heparins, novel oral anticoagulants), antiarrhythmic drugs (AADs), digoxin, thiazide diuretics, and hydralazine/isosorbide dinitrate (Table 1).

Patients were considered to be taking a given medication within a therapeutic class pre LVAD if they filled a medication within 90 days before hospital admission for LVAD surgery. Medication use in the year after LVAD was evaluated in 3-month intervals (0–3, 3–6, 6–9, and 9–12 months) beginning from the date of hospital discharge after LVAD surgery. Patients were considered to be taking a given medication class post LVAD upon filling a prescription for a medication within that therapeutic class. Medication adherence was examined for the most commonly used medication classes after LVAD (β-blockers, ACEI/ARB, loop diuretics, anticoagulants). We considered medications in the same therapeutic class substitutable, therefore we did not double-count the overlapped days for different drugs in the same class. We used pharmacy-based proportion of days covered (PDC) to quantify medication adherence during the 1-year period post LVAD. For each medication class, the PDC was defined as the proportion of days for which the patient had medication available to take (based on all fills) divided by the number of days in their follow-up period. The first day for both the numerator and denominator of the PDC began on the first day that the prescription was filled. A PDC ≥80% was used to define adherence. If patients were hospitalized during the follow-up period, hospitalization days were added to the numerator of the PDC calculation. Patients who did not fill a prescription for a particular medication class were not included in the analysis of adherence for that medication class. We performed a continuation analysis to better understand whether patients with poor adherence during follow-up discontinued use of a medication class completely. Discontinuation was defined as failing to refill a given medication class for at least 90 days after the supply ended.

### Table 1. List of Medications Used for Heart Failure in the Current Study

| ACEIs/ARBs | β-Blockers | Loop Diuretics | MRAs | Thiazide Diuretics | Anticoagulants | Antiarrhythmics |
|------------|------------|----------------|------|--------------------|----------------|-----------------|
| Benazepril | Carvedilol | Bumetanide     | Spironolactone | Chlorothiazide | Dicumarol       | Amiodarone       |
| Captopril  | Sotalol    | Ethacrynic acid| Eplerenone   | Hydrochlorothiazide | Warfarin      | Dofetilide       |
| Enalapril  | Acebutolol | Furosemide     | Indapamide   | Dalteparin      | Enoxaparin     | Flecainide       |
| Fosinopril | Atenolol   | Torsemide      | Metolazone   | Dronedarone     |                |                 |
| Lisinopril | Bisoprolol |                |            |                |                |                 |
| Perindopril| Metoprolsuccinate |                |            |                |                |                 |
| Quinapril  | Metoprol tartrate |                |            |                |                |                 |
| Candesartan| Telmisartan|                |            |                |                |                 |
| Ramipril   | Nadolol    |                |            |                |                |                 |
| Trandolapril| Nebivolol |                |            |                |                |                 |
| Moexipril  | Propanolol |                |            |                |                |                 |
| Valsartan  | Labetalol  |                |            |                |                |                 |
| Azilsartan | Betaxolol  |                |            |                |                |                 |
| Irbesartan | Penbutolol |                |            |                |                |                 |
| Losartan   | Pindolol   |                |            |                |                |                 |
| Olmesartan | Timolol    |                |            |                |                |                 |
| Eprosartan |            |                |            |                |                |                 |

Intravenous and ocular preparations of medications were not included. If a medication was taken as a part of a combination medication (such as amlodipine/benazepril), that was also counted toward angiotensin-converting enzyme inhibitor (ACEI) use. Other medications included in their own categories were (1) digoxin and (2) hydralazine used in combination with isosorbide dinitrate. ARBs indicates angiotensin receptor blockers; MRAs, mineralocorticoid receptor antagonists.
appropriate. Differences in the proportion of patients taking medications of interest before compared with after LVAD implantation were examined using McNemar test. Predictors of post-LVAD medication use and adherence for the most commonly prescribed medication classes were examined using logistic regression. Post-LVAD medication use was defined as filling a medication in a given therapeutic class within 90 days of hospital discharge after LVAD implantation. Nonadherence to a given medication class was defined as a PDC <80%. Variables were chosen a priori and were limited based on sample size. Results are presented using odds ratios (ORs) and 95% confidence intervals (CIs). Changes in the proportion of patients taking medication classes over time (0–3, 3–6, 6–9, and 9–12 months) post LVAD were examined using linear regression. All analyses were performed using SAS version 9.3. A P value cutoff of <0.05 was used to determine statistical significance.

Results

Baseline Characteristics

A total of 1230 patients who underwent LVAD implantation within the study period were identified; 362 patients had medical and pharmacy coverage 6 months prior and 90 days post LVAD, and did not undergo heart transplantation either during their LVAD hospitalization or 3 months post LVAD. The mean age was 57.4 years (SD 12.4), and 75.1% were men (Table 2). In total, 47.2% of patients with LVAD had diabetes mellitus, 70.2% had hypertension, 39.5% had moderate or severe renal disease, 29.6% had cerebrovascular disease, and 46.4% had atrial fibrillation and/or atrial flutter. The majority of LVADs were implanted in hospitals located in “metro” areas (81.4%) with ≥400 beds (89.6%) and that identified themselves as teaching centers (78.9%). In total, 222 (61.3%) had a full year of follow-up after LVAD hospital discharge, whereas the remainder disenrolled or underwent heart transplantation before 1 year post-LVAD.

Medication Use Before and Following LVAD Implantation

Before LVAD implantation, the majority of patients were taking β-blockers (65.5%), loop diuretics (65.5%), and ACEIs/ARBs (56.1%), while about half (48.6%) were taking MRAs (Table 3). Among those taking β-blockers (n=237), the most commonly used were carvedilol (74.3% of patients), metoprolol succinate (19.0%), and metoprolol tartrate (11.4%). Among those taking AADs (n=100), the most commonly used were amiodarone (83.0% of patients), mexiletine (13.0%), and sotalol (13.0%). Of patients taking anticoagulants before LVAD (n=134), the majority were taking warfarin (85.1%); 17 patients were taking novel oral anticoagulants pre LVAD (9 rivaroxaban, 7 dabigatran, and 1 apixaban).

Post LVAD, the proportion of patients using β-blockers (63.3%), loop diuretics (68.2%), and ACEIs/ARBs (53.9%) did not change (P=0.56, 0.38, and 0.57, respectively). However, the proportion of patients taking MRAs decreased from 48.6% to 37.6% (P=0.002). In comparison, the proportion of patients taking AADs increased from 27.6% to 48.6% following LVAD placement (P<0.001). The use of anticoagulants increased from 37.0% pre-LVAD to 82.0% post-LVAD implantation (P<0.001). The use of thiazide diuretics and digoxin decreased after LVAD implantation. There were few patients taking hydralazine/isosorbide dinitrate either pre or post LVAD. There were no significant differences in the proportion of patients taking each class of medication by the 3-month time period in the year after LVAD (Figure; P>0.05 for each medication class).

Similar to pre LVAD, the most commonly prescribed β-blockers post LVAD were carvedilol (66.4% of 229 patients), metoprolol Succinate (21.4%), and metoprolol succinate (21.0%). Of the 176 patients taking AAD post LVAD, the majority were using amiodarone (89.8%). In alignment with device recommendations, nearly all patients using anticoagulants post LVAD were taking warfarin (294 of 297, 99.0%), although some also filled prescriptions for enoxaparin (n=69, 23.2%) or fondaparinux (n=2, 0.7%). No patients used novel oral anticoagulants after LVAD.

The univariate predictors of post-LVAD medication use are shown in Table 4. β-Blocker use post LVAD was greater in men compared with women, with an OR of 1.97 (95% CI, 1.21–3.19). ACEI/ARB use was lower among patients with moderate/severe renal disease (OR, 0.49; 95% CI, 0.32–0.75). Past arrhythmias were associated with post-LVAD AAD use (OR, 2.71; 95% CI, 1.55–4.75). Across all medication classes, prior medication use within the same class was associated with post-LVAD medication use.

Anticoagulant use was not significantly associated with a history of cerebrovascular disease or gastrointestinal bleeding. We also examined whether patients who did not fill an anticoagulation prescription had a stroke or gastrointestinal bleed early after LVAD. In the total population, 4 (1.1%) patients had a stroke and 26 (7.2%) had a gastrointestinal bleed between admission for LVAD implantation and 90 days post-LVAD hospital discharge, respectively. Of patients who were not initiated on anticoagulation following LVAD, 1 (1.6%) had a stroke and 7 (10.9%) had gastrointestinal bleeding early after LVAD.

Medication Adherence Post-LVAD Implantation

Poor medication adherence after LVAD was common. In total, 28.8% (66/229), 39.0% (76/195), 36.0% (107/297), and
55.9% (138/247) of patients were nonadherent to β-blockers, ACEIs/ARBs, anticoagulants, and loop diuretics, respectively. On univariate analysis, pre-LVAD use was associated with decreased odds of nonadherence for β-blockers and loop diuretics, with ORs of 0.44 (95% CI, 0.24–0.81) and 0.39 (95% CI, 0.21–0.75), respectively. A Charlson comorbidity index of 5 or more was associated with increased odds of nonadherence to anticoagulants (OR, 2.80; 95% CI, 1.00–7.88); however, no evidence of an association between comorbidity burden and adherence to β-blockers, ACEIs/ARBs, and loop diuretics was found.

### Table 2. Baseline Characteristics of 362 Patients With LVAD

| Characteristic (Total, N=362) | Value |
|-------------------------------|-------|
| Age, mean (SD), y             | 57.4 (12.4) |
| Age group, No. (%), y         |       |
| 18–34                         | 21 (5.8) |
| 35–44                         | 31 (8.6) |
| 45–54                         | 71 (19.6) |
| 55–64                         | 138 (38.1) |
| 65+                           | 101 (27.9) |
| Sex, No. (%), y               |       |
| Female                        | 90 (24.9) |
| Male                          | 272 (75.1) |
| Race, No. (%), y              |       |
| White                         | 236 (65.2) |
| Black                         | 77 (21.3) |
| Asian                         | 8 (2.2) |
| Hispanic                      | 28 (7.7) |
| Unknown/missing               | 13 (3.6) |
| Year of LVAD implantation, No. (%) |       |
| 2006                          | 6 (1.7) |
| 2007                          | 15 (4.1) |
| 2008                          | 18 (5.0) |
| 2009                          | 25 (6.9) |
| 2010                          | 37 (10.2) |
| 2011                          | 58 (16.0) |
| 2012                          | 55 (15.2) |
| 2013                          | 63 (17.4) |
| 2014                          | 68 (18.8) |
| 2015                          | 17 (4.7) |
| LVAD hospitalization length of stay, mean (SD) | 41.4 (29.8) |
| Length of follow-up, mean (SD), d | 486.2 (409.7) |
| Charlson index, mean (SD)     | 4.5 (2.5) |
| Medical comorbidities, No. (%), y |       |
| Diabetes mellitus             | 171 (47.2) |
| Hypertension                  | 254 (70.2) |
| Myocardial infarction         | 122 (33.7) |
| Cerebrovascular disease       | 107 (29.6) |
| Moderate/severe renal disease | 143 (39.5) |
| Chronic obstructive pulmonary disease | 187 (51.7) |
| Gastrointestinal bleeding     | 32 (8.8) |
| Cardiac arrhythmias           | 291 (80.4) |

### Table 2. Continued

| Characteristic (Total, N=362) | Value |
|-------------------------------|-------|
| Hospital location, No. (%)    |       |
| Division                      | 52 (18.6) |
| Metro                         | 228 (81.4) |
| Bed size, No. (%)             |       |
| 50–199                        | 3 (1.1) |
| 200–399                       | 26 (9.3) |
| 400+                          | 251 (89.6) |
| Teaching status, No. (%)      |       |
| Teaching                      | 221 (78.9) |
| Nonteaching                   | 59 (21.1) |
| Geographic region             |       |
| Northeast                     | 19 (6.5) |
| South                         | 122 (43.6) |
| Midwest                       | 113 (40.4) |
| West                          | 26 (9.3) |

LVAD indicates left ventricular assist device.

55.9% (138/247) of patients were nonadherent to β-blockers, ACEIs/ARBs, anticoagulants, and loop diuretics, respectively. On univariate analysis, pre-LVAD use was associated with decreased odds of nonadherence for β-blockers and loop diuretics, with ORs of 0.44 (95% CI, 0.24–0.81) and 0.39 (95% CI, 0.21–0.75), respectively. A Charlson comorbidity index of 5 or more was associated with increased odds of nonadherence to anticoagulants (OR, 2.80; 95% CI, 1.00–7.88); however, no evidence of an association between comorbidity burden and adherence to β-blockers, ACEIs/ARBs, and loop diuretics was found.

### Table 3. Medication Use Pre and Post LVAD

| Medication Class | Pre LVAD | Post LVAD | P Value |
|-----------------|----------|-----------|---------|
| β-Blocker       | 237 (65.5) | 195 (53.9) | 0.56    |
| ACEI/ARB        | 203 (56.1) | 229 (63.3) | 0.57    |
| Antiarrhythmic  | 100 (27.6) | 176 (48.6) | <0.001  |
| Anticoagulant   | 134 (37.0) | 297 (82.0) | <0.001  |
| MRA             | 176 (48.6) | 136 (37.6) | 0.002   |
| Loop diuretic   | 237 (65.5) | 247 (68.2) | 0.38    |
| Thiazide diuretic| 91 (25.1) | 33 (9.1) | <0.001  |
| Hydralazine and isosorbide dinitrate | 3 (0.8) | 9 (2.5) | 0.65    |
| Digoxin         | 111 (30.7) | 70 (19.3) | <0.001  |

All values are shown as number (percentage). ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; LVAD, left ventricular assist device; MRA, mineralocorticoid receptor antagonist.
diuretics was detected. Age, sex, and race/ethnicity were not significantly associated with adherence to any of the medication classes (Table 5).

Many patients who were nonadherent completely discontinued use of β-blockers (18/66, 27.3% of nonadherent), ACEIs/ARBs (34/76, 44.7%), anticoagulants (28/107, 26.2%), and loop diuretics (62/138, 44.9%) during follow-up.

**Discussion**

In this study, we examined the longitudinal use of HF medications before and following LVAD implantation in a large group of individuals enrolled in private and Medicare Advantage health plans. There were a number of important findings from our analysis. First, many patients were not taking neurohormonal medications before LVAD implantation. Second, the only consistent predictor of post-LVAD medication use was pre-LVAD use of a medication in the same therapeutic class. Third, use of some classes of medications changed after LVAD. In particular, AAD and anticoagulant use increased, whereas use of MRAs decreased. Furthermore, there was no use of novel oral anticoagulants after LVAD, although many patients received low-molecular-weight heparin. Finally, some patients had poor medication adherence following LVAD implantation, many of whom discontinued use of medications such as β-blockers and ACEIs/ARBs completely.

With the advent of continuous-flow device technology, the number of LVAD implantations being performed across the United States, particularly in the context of destination therapy, has continued to rise. These devices provide a means of mechanically unloading the heart, with consequent restoration of cardiac output and correction of the left-sided volume-mediated neurohormonal axis. However, little is known about how to optimally medically manage patients with LVADs. While a wealth of clinical trial data exist to guide the use of traditional HF medications (such as β-blockers and ACEIs/ARBs) in patients with HF with reduced ejection fraction, similar data to guide the management of patients with LVADs are not available. Accordingly, the most recent ISHLT LVAD guidelines recommended use of these HF medications in patients with LVADs based only on consensus agreement (level of evidence C). As a result of the lack of outcomes data to guide therapy, the use of HF medications after LVAD may vary. Understanding the current medical management of patients on LVAD support is hence an important first step toward defining best practices.

The pre-LVAD use of HF medications in our study appeared lower compared with rates previously documented in patients with clinically stable HF. This was not surprising given that patients with advanced HF are apt to be less tolerant of neurohormonal antagonists. In addition, the overall comorbidity burden of our study population was high, with a significant proportion experiencing concomitant renal, vascular, and pulmonary diseases, which may limit use of HF medications. The pre-LVAD medication use we observed also differed somewhat from that reported in the INTERMACS registry. Use of ACEIs/ARBs (56% versus 38%), β-blockers...
While the use of some medication classes changed after LVAD, the proportion of patients using β-blockers and ACEIs/ARBs post-LVAD implantation did not. In theory, patients may better tolerate β-blockers and ACEIs/ARBs given the hemodynamic stabilization conferred by mechanical circulatory support. However, similar use of these medications post LVAD as compared with pre LVAD may reflect the uncertainty and lack of clear guidance that clinicians have in medically managing patients post LVAD, resulting in a tendency to simply continue pre LVAD therapies. As evidence of this phenomenon, the only consistent predictor of post-LVAD medication use observed in this study was use of a medication in the same therapeutic class pre LVAD. On the other hand, MRA use declined following LVAD implantation. In the pivotal RALES (Randomized Aldactone Evaluation Study), spironolactone showed mortality benefit as an adjunctive therapy to β-blockers and ACEIs/ARBs. Whether there is therapeutic benefit associated with MRA use in patients with LVADs is a question that has not been studied. As such, providers may discontinue them in an effort to simplify medical regimens. Other factors such as hypotension and renal insufficiency may also contribute to the decreased use of MRAs post LVAD.

### Table 4. Univariate Predictors of Post-LVAD Medication Use

| Variable            | Odds Ratio (95% CI) | β-Blockers | ACEIs/ARBs | AADs | Anticoagulants | MRAs | Loop Diuretics |
|---------------------|---------------------|------------|------------|------|----------------|------|----------------|
| Age group, y        |                     |            |            |      |                |      |                |
| 18–34               | REF                 | REF        | REF        |      | REF            | REF  | REF            |
| 35–44               | 0.80 (0.26–2.44)    | 1.42 (0.47–4.34) | 0.79 (0.26–2.42) | 0.48 (0.11–2.07) | 0.47 (0.15–1.46) | 0.41 (0.10–1.73) | REF |
| 45–54               | 2.05 (0.75–5.64)    | 2.61 (0.97–7.06) | 1.13 (0.43–3.00) | 0.82 (0.21–3.23) | 0.41 (0.15–1.10) | 0.29 (0.08–1.07) | REF |
| 55–64               | 1.60 (0.63–4.08)    | 2.01 (0.80–5.10) | 1.31 (0.52–3.28) | 1.11 (0.30–4.16) | 0.53 (0.21–1.34) | 0.41 (0.11–1.46) | REF |
| 65+                 | 0.90 (0.35–2.32)    | 0.87 (0.34–2.27) | 0.78 (0.31–2.01) | 0.54 (0.15–1.97) | 0.32 (0.12–0.83) | 0.29 (0.08–1.05) | REF |
| Sex                 |                     |            |            |      |                |      |                |
| Female              | REF                 | REF        | REF        |      | REF            | REF  | REF            |
| Male                | 1.97 (1.21–3.19)*   | 0.81 (0.50–1.31) | 1.18 (0.73–1.90) | 1.20 (0.65–2.19) | 0.87 (0.54–1.42) | 0.90 (0.53–1.50) | REF |
| Race                |                     |            |            |      |                |      |                |
| White               | REF                 | REF        | REF        |      | REF            | REF  | REF            |
| Asian               | 0.99 (0.23–4.25)    | 2.76 (0.55–13.94) | 1.11 (0.27–4.53) | …   | 0.57 (0.11–2.89) | 3.13 (0.38–25.93) | REF |
| Black               | 1.17 (0.68–2.00)    | 1.10 (0.66–1.85) | 1.14 (0.68–1.90) | 0.89 (0.45–1.75) | 0.87 (0.51–1.50) | 1.05 (0.60–1.84) | REF |
| Hispanic            | 1.07 (0.47–2.42)    | 1.94 (0.84–4.46) | 1.48 (0.67–3.26) | 0.73 (0.28–1.91) | 2.65 (1.19–5.91)* | 0.81 (0.36–1.83) | REF |
| Unknown/missing     | 0.69 (0.23–2.13)    | 0.57 (0.18–1.81) | 0.69 (0.22–2.18) | 0.23 (0.07–0.73)* | 0.76 (0.23–2.55) | 0.28 (0.08–0.89) | REF |
| Pre-LVAD use        | 1.78 (1.14–2.77)*   | 1.95 (1.28–2.96)* | 3.66 (2.23–6.02)* | 3.47 (1.74–6.91)* | 1.76 (1.14–2.70)* | 4.55 (2.83–7.30)* | REF |
| Myocardial infarction| 0.94 (0.60–1.47)   | 1.24 (0.80–1.92) | 1.39 (0.90–2.16) | 0.84 (0.48–1.47) | 0.86 (0.55–1.35) | 1.11 (0.69–1.77) | REF |
| Diabetes mellitus   | 1.34 (0.87–2.06)    | 1.14 (0.75–1.73) | 1.04 (0.69–1.57) | 0.95 (0.56–1.63) | 1.02 (0.67–1.57) | 1.15 (0.74–1.79) | REF |
| Hypertension        | 1.21 (0.76–1.92)    | 0.96 (0.61–1.50) | 1.49 (0.95–2.35) | 1.37 (0.78–2.41) | 0.83 (0.52–1.31) | 1.32 (0.82–2.13) | REF |
| Congestive heart failure | 0.62 (0.35–1.09) | … | 2.71 (1.55–4.75)* | … | … | … |
| Renal disease       | …                   | 0.49 (0.32–0.75)* | … | … | 0.73 (0.48–1.13) | 1.37 (0.87–2.14) | REF |
| CVD                 | …                   | … | … | 1.02 (0.57–1.84) | … |
| GIB                 | …                   | … | … | 2.24 (0.66–7.58) | … |

... indicates not performed. AAD indicates antiarrhythmic drugs; ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CI, confidence interval; CVD, cerebrovascular disease; GIB, gastrointestinal bleeding; LVAD, left ventricular assist device; MRAs, mineralocorticoid receptor antagonists; REF, reference category. *P<0.05.

(66% versus 55%), MRAs (49% versus 40%), and warfarin (34% versus 22%) was higher pre LVAD in our population compared with in the INTERMACS registry. In the INTERMACS registry, medications are entered into a case report form based on current or prior use as documented in the patient’s medical record, which can include patient report and/or prescriptions ordered. It does not take into account whether prescriptions were ever filled by patients. Thus, it is unclear whether our findings reflect actual differences in medication use in the populations studied versus failure to capture pre-LVAD medication use accurately in the INTERMACS registry.
In the absence of severe recurrent bleeding, use of anticoagulants is required after LVAD to maintain pump patency, thus it is not surprising that their use increased post-LVAD. Even so, almost 20% of patients did not have pharmacy claims for anticoagulation in the 90 days after LVAD. A small number of patients had a stroke or gastrointestinal bleeding early after LVAD, which could partially account for the results observed. However, it is also plausible that, given the cost of warfarin, some patients might have elected to pay out-of-pocket without involving insurance coverage. However, even in INTERMACS, 10% to 15% of patients were not documented as taking warfarin after LVAD.5 We also found that nearly one quarter of patients used enoxaparin in the year after LVAD. While no guidelines exist to support its use after LVAD, it has been shown to have biologic efficacy in the LVAD population.25 Although there has been interest in understanding whether it is safe to use novel oral anticoagulants as an alternative to warfarin post-LVAD implantation,26 we saw no evidence of their use in our study. Finally, AAD use was also significantly increased following LVAD placement. Ventricular arrhythmias occur in approximately one third of patients with LVAD, with the highest incidence observed during the first 2 weeks of mechanical support,27,28 thereby providing a plausible explanation for the observed increase in use.

To the best of our knowledge, this is the first study to examine medication adherence after LVAD. We found that a substantial proportion of patients had poor adherence to medications such as β-blockers and ACEIs/ARBs following LVAD implantation. However, many patients with poor adherence discontinued use of medications in that class completely. We cannot determine whether patients discontinued use after discussing with their physician, and whether discontinuation was caused by intolerance or other reasons. Pre-LVAD medication use was significantly associated with

### Table 5. Univariate Predictors of Medication Nonadherence

| Age group, y | β-Blockers | ACEIs/ARBs | Anticoagulants | Loop Diuretics |
|--------------|------------|------------|----------------|---------------|
|              | No.* Odds Ratio (95% CI) | No.* Odds Ratio (95% CI) | No.* Odds Ratio (95% CI) | No.* Odds Ratio (95% CI) |
| 18–34        | REF 6      | REF 5      | REF 5          | REF 11        |
| 35–44        | 3 0.23 (0.04–1.25) | 6 0.48 (0.09–2.52) | 12 2.84 (0.76–10.58) | 10 0.53 (0.15–1.88) |
| 45–54        | 11 0.27 (0.07–1.00) | 15 0.38 (0.09–1.60) | 16 0.97 (0.30–3.15) | 25 0.80 (0.26–2.43) |
| 55–64        | 24 0.34 (0.10–1.17) | 28 0.41 (0.10–1.64) | 43 1.45 (0.49–4.35) | 49 0.64 (0.23–1.78) |
| 65+          | 22 0.67 (0.19–2.34) | 22 0.98 (0.23–4.19) | 31 1.75 (0.57–5.41) | 43 1.30 (0.44–3.84) |

| Sex          | Female | 14 REF | 20 REF | 19 REF | 36 REF |
|--------------|--------|--------|--------|--------|--------|
| Male         | 52     | 56     | 88     | 102    |

| Race         | White  | 46 REF | 48 REF | 73 REF | 99 REF |
|--------------|--------|--------|--------|--------|--------|
| Black        | 12     | 0.56 (0.06–5.10) | 16     | 0.78 (0.14–4.43) | 24     | 1.02 (0.24–4.39) | 26     | 0.49 (0.11–2.24) |
| Hispanic     | 4      | 0.68 (0.33–1.42) | 7      | 0.96 (0.47–1.98) | 4      | 1.05 (0.58–1.88) | 8      | 0.60 (0.32–1.12) |
| Asian        | 3      | 0.63 (0.20–2.03) | 2      | 0.91 (0.34–2.48) | 3      | 0.38 (0.12–1.16) | 3      | 0.52 (0.19–1.38) |
| Unknown/missing | 1 | 1.66 (0.36–7.74) | 3 | 2.34 (0.38–14.54) | 3 | 1.27 (0.28–5.85) | 2 | 0.43 (0.07–2.65) |

| Charlson comorbidity index | 0 or 1 | 3 REF | 7 REF | 5 REF | 13 REF |
|---------------------------|--------|--------|--------|--------|--------|
| 2                         | 15     | 3.25 (0.78–13.48) | 12     | 1.21 (0.37–3.98) | 15     | 2.44 (0.77–7.78) | 17     | 0.44 (0.14–1.34) |
| 3                         | 7      | 1.01 (0.23–4.54) | 14     | 0.96 (0.31–3.00) | 20     | 2.93 (0.95–9.03) | 25     | 1.04 (0.33–3.23) |
| 4                         | 13     | 1.88 (0.46–7.72) | 13     | 1.39 (0.43–4.56) | 18     | 2.33 (0.76–7.19) | 26     | 0.70 (0.24–2.08) |
| ≥ 5                       | 28     | 1.73 (0.46–6.55) | 30     | 1.05 (0.37–2.96) | 49     | 2.80 (1.00–7.88) | 57     | 0.64 (0.24–1.73) |

| Pre-LVAD use | No | 28 REF | 33 REF | 57 REF | 42 REF |
|--------------|----|--------|--------|--------|--------|
| Yes          | 38 | 0.44 (0.24–0.81)† | 43 | 0.61 (0.34–1.11) | 50 | 1.41 (0.87–2.27) | 96 | 0.39 (0.21–0.75)† |

ACEIs/ARBs indicates angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CI, confidence interval; LVAD, left ventricular assist device; REF, reference category.

*Number of nonadherent patients in each category.

†P < 0.05.

DOI: 10.1161/JAHA.117.005776

Journal of the American Heart Association

8
better adherence for β-blockers and loop diuretics; familiarity with and tolerance of these medications before LVAD placement may have contributed to better adherence post-LVAD. Studies have demonstrated that nonadherence to HF treatments is associated with increased risk of hospital readmission and death, and that interventions to improve adherence can improve these outcomes.α,3,19 Further work is needed to delineate the reasons for nonadherence after LVAD and examine the associations of nonadherence and outcomes.

Study Limitations

First, the Optum Labs Data Warehouse includes individuals enrolled in private and Medicare Advantage health plans, and findings may not be generalizable to populations with other health insurance types. Second, medications purchased out-of-pocket (without submitting to insurance) would not be captured in our analysis. Third, we do not have information on the LVAD models used or their indication (bridge-to-transplant or destination therapy). Fourth, as with any claims-based study, there is potential for misclassification when relying on billing codes to identify comorbidities. Finally, as with all research conducted using pharmacy claims, we were unable to distinguish whether patients stopped a medication based on physician instruction or of their own accord. Reasons for poor adherence could not be determined and would be of interest to examine in future studies.

Conclusions

The use of β-blockers and ACEIs/ARBs, the cornerstones of HF medical therapy, did not increase following LVAD implantation. Medication adherence post LVAD was suboptimal in many patients. Further studies are needed to determine the optimal use of HF medications after LVAD.

Sources of Funding

The study was funded by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Dr Dunlay is funded by a National Institutes of Health Career Development Award (K23 HL 116643).

Disclosures

None.

References

1. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Ullisney KL, Baldwin JT, Young JB. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011;30:115–123.
2. Schaff HV, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM III, Long JW, Wozniak TC, Gummerman W, Farrar DJ, Frazier OH; HeartMate III. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251.
3. Khazanie P, Hammill BG, Patel CB, Eapen ZJ, Peterson ED, Rogers JG, Milano CA, Curtis LH, Hernandez AF. Trends in the use and outcomes of ventricular assist devices among Medicare beneficiaries, 2006 through 2011. J Am Coll Cardiol. 2014;63:1395–1404.
4. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El-Banayosi A, Elliott T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaa A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohaci P, Mooney M, Nelson T, Pagni F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32;157–187.
5. Khazanie P, Hammill BG, Patel CB, Kienan MS, Cooper LB, Arnold SV, Fendler TJ, Spterus JA, Curtis LH, Hernandez AF. Use of heart failure medical therapies among patients with left ventricular assist devices: insights from INTERMACS. J Card Fail. 2016;22;672–679.
6. Deschaseaux C, McSharry M, Hudson E, Agrawal R, Turner SJ. Treatment initiation patterns, modifications, and medication adherence among newly diagnosed heart failure patients: a retrospective claims database analysis. J Manag Care Spec Pharm. 2016;22;561–571.
7. Dunlay SM, Eveleth JM, Shah ND, McManan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc. 2011;86;273–281.
8. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117;1028–1036.
9. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297;177–186.
10. Dunlay SM, Haas LR, Herrin J, Schilt SR, Stulak JM, Kushwaha SS, Shah ND. Use of post-acute care services and readmissions after left ventricular assist device implantation in privately insured patients. J Card Fail. 2015;21;816–823.
11. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood). 2014;33;1187–1194.
12. Wallace PM. Optum Labs-Partners, Data and Design. 2015; Available at https://www.optum.com/content/dam/optum/Landing%20Page/files/Op mumData y2015_1_OptumLabs_P.Wallace.pdf. Accessed September 14, 2017.
13. Hwang W, Weller W, Ieys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood). 2001;20;267–278.
14. Naessens JM, Stroebel RJ, Finnie DM, Shah ND, Wogie AE, Litchy WJ, Killinger PJ, O’Byrne TJ, Wood DL, Nesse RE. Effect of multiple chronic conditions among working-age adults. Am J Manag Care. 2011;17;118–122.
15. Quan H, Sundararajan V, Halfon P, Loomis JR, Wann S, Looze PM, Moazami N, Mohaci P, Mooney M, Nelson T, Pagni F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32;157–187.
16. Hess LM, Raelbel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40;1280–1288.
17. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119;3028–3035.
18. Mancini D, Colombo PC. Left ventricular assist devices: a rapidly evolving alternative to transplant. J Am Coll Cardiol. 2015;65;2542–2555.
19. Burkhoff D, Klotz S, Mancini DM. LVAD-induced reverse remodeling: basic and clinical implications. J Card Fail. 2006;12;27–39.
20. Drakos SG, Kfoury AG, Selzman CH, Verma DR, Nanas JN, Li DY, Stehlik J. Left ventricular assist device unloading effects on myocardial structure and function: current status of the registry and call for action. Curr Opin Cardiol. 2011;26;245–255.
21. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Inge JP, Mehra MR, O’Connor CM, Rehman DS, Walsh MN, Yancy CW. Improving evidence-based care for heart failure in outpatient cardiologist practices: primary results of the Registry to Improve the Use of Evidence-based Care for heart failure in Outpatient Cardiology (Registry to Improve the Use of Evidence-based Care for heart failure in Outpatient Cardiology or Registry). JAMA. 2011;305;2555–2563.
23. Kirklin JK, Naftel DC, Stevenson LW, Kormos RL, Pagani FD, Miller MA, Ullsney K, Young JB. INTERMACS database for durable devices for circulatory support: first annual report. *J Heart Lung Transplant*. 2008;27:1065–1072.

24. Pitt B, Zannad F, Remme WJ, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*. 1999;341:709–717.

25. Sandner SE, Riebandt J, Haberl T, Mahr S, Rajek A, Schima H, Wieselthaler GM, Laufer G, Zimpfer D. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation. *J Heart Lung Transplant*. 2014;33:88–93.

26. DeVore AD, Milano CA, Rogers JG. VAD therapy 20/20: moving beyond the myopic view of a nascent therapy. *Ann Cardiothorac Surg*. 2014;3:603–605.

27. Pedrotty DM, Rame JE, Margulies KB. Management of ventricular arrhythmias in patients with ventricular assist devices. *Curr Opin Cardiol*. 2013;28:360–368.

28. Raasch H, Jensen BC, Chang PP, Mounsey JP, Gehi AK, Chung EH, Sheridan BC, Bowen A, Katz JN. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. *Am Heart J*. 2012;164:373–379.

29. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials. *J Am Heart Assoc*. 2016;5:e002606. DOI: 10.1161/JAHA.115.002606.
SUPPLEMENTAL MATERIAL
Table S1. Variable Definitions

| Variable                      | Baseline Comorbidity or Outcome | ICD Codes                                      |
|-------------------------------|---------------------------------|------------------------------------------------|
| Diabetes mellitus<sup>1, 2</sup> | Comorbidity                     | 250.XX, 253.5                                  |
| Hypertension<sup>1, 2</sup>   | Comorbidity                     | 401.X, 402.XX, 403.XX, 404.00, 404.10, 404.12, 404.13, 404.90, 404.91, 404.92, 404.93, 405.XX, 437.2 |
| Cerebrovascular Disease<sup>1, 2</sup> | Comorbidity                     | 430, 431, 432.1, 432.9, 433.00, 433.1, 433.10, 433.11, 433.20, 433.21, 433.30, 433.31, 433.91, 434.0, 434.00, 434.01, 434.10, 434.11, 434.9, 434.90, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9, 436, 437.0, 437.1, 437.3, 437.4, 437.5, 437.7, 437.8, 437.9, 438, 438.0, 438.10, 438.11, 438.12, 438.19, 438.20, 438.21, 438.22, 438.50, 438.6, 438.7, 438.81, 438.82, 438.83, 438.84, 438.85, 438.89, 438.9 |
| Chronic pulmonary disease<sup>3</sup> | Comorbidity                     | 416.8, 416.9, 490.x- 505.x, 506.4, 508.1, 508.8 |
| Moderate/Severe Renal Disease<sup>3</sup> | Comorbidity                     | 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 582.x, 538-583.7, 585.x, 586.x, 588.x, V42.0, V45.1, V56.x Added 584.X (acute kidney failure) |
| Cardiac Arrhythmias           | Comorbidity                     | 427.x                                          |
| Gastrointestinal Bleeding<sup>4</sup> | Comorbidity and Post-left ventricular assist device outcome | 456.0, 456.20, 530.21, 530.7, 530.82, 531.0x, 531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 535.71, 537.83, 537.84, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.85, 578.x |
| Myocardial Infarction<sup>3</sup> | Comorbidity                     | 410.X, 412.X                                 |
| Stroke/ transient ischemic attack<sup>4</sup> | Post-left ventricular assist device outcome | 430, 431, 433.x1, 434.x1, 435.x, 436 |

Baseline comorbidities were identified by examining diagnosis codes in position 1-3 in the inpatient or outpatient setting. Outcomes (GI bleeding, stroke/ TIA) occurring post-LVAD were examined using inpatient codes in the first and second position. When assessing stroke, events with a primary discharge diagnosis of rehabilitation (ICD-9-CM code V57) or any additional diagnoses of trauma (ICD-9-CM codes 800-804 and 850-854) were excluded. When assessing gastrointestinal bleeding, we excluded the events that had a primary discharge diagnosis of rehabilitation (ICD-9-CM code V57).
Supplemental References:

1. Hwang W, Weller W, Ireys H Anderson G. Out-of-pocket medical spending for care of chronic conditions. *Health Aff (Millwood)*. 2001;20:267-78.

2. Naessens JM, Stroebel RJ, Finnie DM, Shah ND, Wagine AE, Litchy WJ, Killinger PJ, O'Byrne TJ, Wood DL Nesse RE. Effect of multiple chronic conditions among working-age adults. *Am J Manag Care*. 2011;17:118-22.

3. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005;43:1130-9.

4. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, Gersh BJ, Shah ND Noseworthy PA. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. *J Am Heart Assoc*. 2016;5. doi: 10.1161/JAHA.115.003074.